Novo Nordisk Terminates Wegovy Partnership w $HIMS (Patreon)

Hims & Hers’ stock plummeted today due to Novo Nordisk’s termination of their Wegovy partnership, driven by allegations of illegal compounding and deceptive marketing involving unapproved semaglutide from Chinese suppliers. The stock dropped 20%–33%, reflecting significant market concern about the loss of a key revenue driver. While Hims & Hers faces litigation risks and must pivot its strategy, the broader China-related context is limited to the sourcing issue.

Novo Nordisk’s move underscores regulatory and safety concerns in the weight-loss drug market, impacting both companies’ stock prices.

It is one helluva volatile stock